- Randomized, triple-blinded, placebo-controlled two-centre trial of 80 adults undergoing primary breast cancer surgery, with or without axillary dissection.
- Patients received either an ultrasound-guided erector spinae plane block (n=40) or intraoperative IV lidocaine infusion (n=40), both within a standardized multimodal analgesic protocol.
- The 24-hour QoR15 score was 137.7 (SD 17.9) with ESPB versus 136.3 (SD 8.8) with IVLI, p=0.61.
- Pain scores, opioid use and rescue analgesia were similarly low in both groups, and the authors suggest IVLI may be a pragmatic option when regional expertise is limited.
Pharmacology
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- This PRISMA-ScR scoping review screened 2,187 records and included 12 studies of ketamine with pain and depression outcomes assessed longitudinally.
- Eight studies enrolled chronic pain patients and four enrolled depression-primary populations, while acute, perioperative, perinatal, and cancer-related pain were excluded.
- Most studies reported concurrent improvement in pain and depressive symptoms, but the abstract gives no pooled effect size.
- The authors conclude that heterogeneity in populations, dosing, design, and comorbidity prevents inferring that depression modifies ketamine's analgesic effect, and call for randomized trials.
AI summary not available. Read the source abstract on PubMed.
AI summary not available. Read the source abstract on PubMed.
- Systematic review and meta-analysis of 165 randomised trials, including 19,124 adults receiving rocuronium or vecuronium for elective procedures.
- Sugammadex 2 mg/kg was compared with neostigmine 0.05 mg/kg for neuromuscular blockade reversal, though risk of bias across trials was generally unclear or high.
- Sugammadex shortened time to a train-of-four ratio above 0.9 by 10.49 minutes (95% CI -11.90 to -9.08; moderate GRADE) and lowered the risk of at least one adverse event (RR 0.72, 95% CI 0.61 to 0.84).
- The authors conclude sugammadex probably reverses blockade faster with fewer adverse events, including residual blockade, desaturation and bradycardia, though the evidence is rated moderate certainty.
- Meta-analysis of 22 RCTs including 4161 older surgical patients under general anesthesia, searched across PubMed, Embase and CENTRAL through July 2026.
- Compared perioperative intravenous dexmedetomidine with control for prevention of postoperative delirium, the primary outcome.
- Dexmedetomidine reduced postoperative delirium (RR 0.56, 95% CI 0.47 to 0.66; P<0.00001; I² 24%) and PONV (RR 0.79, 95% CI 0.62 to 0.99; P=0.04).
- Dexmedetomidine was associated with more intraoperative and postoperative bradycardia and more intraoperative hypotension.
AI summary not available. Read the source abstract on PubMed.
- Single-centre, double-blind randomised noninferiority trial of 686 adults having elective neurovascular surgery, analysed as a modified intention-to-treat population.
- Patients received remimazolam-based TIVA with flumazenil reversal at emergence or propofol-based TIVA, both with remifentanil.
- Postoperative delirium within 5 days occurred in 12.8% (44/344) with remimazolam and 10.8% (37/342) with propofol; risk difference 1.97 percentage points (95% CI -2.85 to 6.80).
- Remimazolam met the prespecified noninferiority criterion, and that group had less intraoperative hypotension below a MAP of 65 mm Hg and more operating-room extubation.
- Systematic review and meta-analysis of five randomized trials, totaling 1613 adults aged 60 or older having surgery under regional anesthesia.
- Compared intraoperative dexmedetomidine with propofol, with delirium assessed using CAM or CAM-ICU.
- Delirium occurred in 7.7% of dexmedetomidine patients versus 16.7% with propofol (RR 0.48, 95% CI 0.36-0.64; P < .001), with low heterogeneity (I² = 13.4%).
- The authors conclude dexmedetomidine is associated with less postoperative delirium, and they rated the certainty of evidence as moderate by GRADE.
- Randomized, double-blind, placebo-controlled single-center trial of 70 patients undergoing on-pump CABG.
- Patients received intranasal dexmedetomidine 1 μg/kg or saline on the night before surgery and again 30 minutes before induction.
- At 24 hours, estimated marginal mean hs-cTnT was 170.29 vs 357.29 ng/L (P < 0.001) favoring dexmedetomidine; CK-MB was also lower.
- Sleep quality scores were higher and postoperative delirium was lower (14.3% vs 37.1%; P = 0.029), but the authors call the findings preliminary.
AI summary not available. Read the source abstract on PubMed.
- Randomized block study in adult Sprague Dawley rats using viral constructs to express channelrhodopsin or a control protein in tyrosine hydroxylase-positive VTA neurons.
- Optogenetic stimulation of these neurons was tested during sevoflurane, dexmedetomidine, fentanyl, and ketamine unconsciousness, with and without light.
- Photostimulation restored sevoflurane-anesthetized righting at a median 4.7 min (95% CI, 2.6 to 6.4); after dexmedetomidine, hazard ratio 27.7 (95% CI, 2.7 to 287.1; P = 0.0053).
- Effects were agent specific: no change after fentanyl, a modest delay in ketamine emergence, and the authors suggest distinct and sometimes opposing pathways shape the role.
- Single-center retrospective before-and-after cohort with propensity matching in a cardiothoracic ICU compared 122 ketamine and 122 control patients after cardiac surgery.
- Patients on an ERAS pathway received a continuous low-dose ketamine infusion (0.1-0.3 mg/kg/h) or no ketamine as the control.
- Cumulative opioid use over POD0-2 was lower with ketamine (30 vs 52.5 MME; p = 0.003), and time to first analgesic was longer (7.4 vs 4.5 h; p < 0.001).
- No hallucinations were seen and urinary retention fell (9.8% vs 34%; p < 0.001), and the authors describe ketamine as a safe adjunct.
- This mini review synthesizes a targeted search of pediatric esketamine studies covering analgesia, sedation, propofol injection pain, and emergence delirium or agitation.
- Randomized trials and meta-analyses generally report fewer emergence delirium or agitation events after low intravenous esketamine doses, mostly during sevoflurane adenotonsillectomy.
- Direct dose-comparison evidence in that setting shows increasing benefit up to 0.5 mg/kg intravenously, with no upper efficacy or safety boundary identified.
- The authors conclude that 0.2-0.5 mg/kg IV was the best-studied range for emergence prevention, not a validated therapeutic window, and call for direct dose-timing trials.
- Randomised, quadruple-blind trial of 90 patients aged 65-100 undergoing primary total knee arthroplasty, comparing dexamethasone adjuncts to adductor canal and iPACK blocks.
- Perineural dexamethasone (4 mg total, 2 mg per block) with ropivacaine was compared with intravenous dexamethasone 4 mg and with placebo.
- Median time to first rescue opioid was 4.5 h with placebo, 13.9 h with IV dexamethasone and 18.5 h with perineural dexamethasone (log-rank p < 0.001).
- Perineural dexamethasone produced lower opioid use than IV at later timepoints, and no motor weakness or nerve injury was reported.